Name：ZHENG Yanbo

Department：Department of oncology

Tel: (8610)63024341

Email: zhengyb@imb.pumc.edu.cn

Education & Research Experience

2014/09 – Now Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2007/08 – 2014/08 Assistant Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences

2004/09 – 2007/07 Ph.D. in microbial and biochemical pharmacy, Peking Union Medical College

Research Field：

Pharmacology of anticancer drugs

Research Interests：

Dr. Zheng’s research focuses on the development of targeted anticancer drugs and investigating the underlying mechanism. The research interests includes microtubule inhibitors, tumor-targeting peptide and drug combinations. The recent research includes 1) First identification of a novel nitrobenzoate microtubule inhibitor IMB5046, 2) Finding that focal adhesion kinase can regulate endothelial blebbing activated by microtubule-depolymerizing agents.

Selected Publications

1. YB Zheng, JH Gong, YS Zhen. Focal adhesion kinase is activated by microtubule-depolymerizing agents and regulates membrane blebbing in human endothelial cells. J Cell Mol Med. 2020, 24(13):7228-7238.

2. YB Zheng, MR Zhang, Y Li, XJ Liu, YS Zhen. DBDx-based drug combinations show highly potent therapeutic efficacy against human pancreatic cancer xenografts in athymic mice. Cancer Biol Ther. 2020, 21(8):749-757.

3. JH Gong, YB Zheng, MR Zhang, YX Wang, SQ Yang, et al. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling. Cancer Biol Ther. 2020, 21(4):332-343.

4. YB Zheng, JH Gong, XJ Liu, Y Li, YS Zhen. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis. Mol Carcinog, 2017, 56(5):1395-1404.

5.YB Zheng, JH Gong, XJ Liu, SY Wu, Y Li, et al. A novel nitrobenzoate microtubule inhibitor that overcomes multidrug resistance exhibits antitumor activity. Sci Rep, 2016, 6:31472.